Menu Search
Equities

Lixte Biotechnology Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8640:MUN

Lixte Biotechnology Holdings Inc

Actions
  • Price (EUR)1.89
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.8633
Data delayed at least 15 minutes, as of Oct 31 2024 14:05 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.13m
  • Incorporated2005
  • Employees2.00
  • Location
    Lixte Biotechnology Holdings Inc433 Plaza Real, Suite 275BOCA RATON 33432United StatesUSA
  • Phone+1 (310) 203-2902
  • Fax+1 (928) 982-5050
  • Websitehttps://lixte.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.